S
Sabina A. Murphy
Researcher at Brigham and Women's Hospital
Publications - 6
Citations - 469
Sabina A. Murphy is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Acute coronary syndrome & Myocardial infarction. The author has an hindex of 6, co-authored 6 publications receiving 429 citations.
Papers
More filters
Journal ArticleDOI
Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I
Marc P. Bonaca,Benjamin M. Scirica,Marc S. Sabatine,Anthony J. Dalby,Jindrich Spinar,Sabina A. Murphy,Peter Jarolim,Eugene Braunwald,David A. Morrow +8 more
TL;DR: Low-level increases in cTnI using a sensitive assay identify patients at higher risk of death or MI, and the incremental value of newer, more sensitive assays in identifying high-risk patients with ACS is supported.
Journal ArticleDOI
Role of ST2 in Non–ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial
Payal Kohli,Marc P. Bonaca,Rahul Kakkar,Anastacia Y. Kudinova,Benjamin M. Scirica,Marc S. Sabatine,Sabina A. Murphy,Eugene Braunwald,Richard T. Lee,David A. Morrow +9 more
TL;DR: ST2 correlates weakly with biomarkers of acute injury and hemodynamic stress but is strongly associated with the risk of HF after NSTE-ACS, and this biomarker and related pathway merit further investigation as potential therapeutic targets for patients with ACS at risk for cardiac remodeling.
Journal ArticleDOI
Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
Ryan G. O'Malley,Marc P. Bonaca,Benjamin M. Scirica,Sabina A. Murphy,Petr Jarolim,Marc S. Sabatine,Eugene Braunwald,David A. Morrow +7 more
TL;DR: These biomarkers improved prognostic discrimination and patient re-classification for CV death or HF at 1 year and are complementary prognostic markers forCV death and HF in patients with NSTE-ACS that perform as well as or better than established and other emerging biomarkers and warrant further investigation of application for therapeutic decision making.
Journal ArticleDOI
Prospective Evaluation of Pregnancy-Associated Plasma Protein-A and Outcomes in Patients With Acute Coronary Syndromes
Marc P. Bonaca,Benjamin M. Scirica,Marc S. Sabatine,Petr Jarolim,Sabina A. Murphy,Janna S. Chamberlin,Daniel W. Rhodes,Paula C. Southwick,Eugene Braunwald,David A. Morrow +9 more
TL;DR: PAPP-A was independently associated with recurrent cardiovascular events in patients with NSTE-ACS and supports PAPP- A as a candidate prognostic marker in Patients with ACS and supports investigation of its therapeutic implications.
Journal ArticleDOI
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
Ragnhild Røysland,Marc P. Bonaca,Torbjørn Omland,Marc S. Sabatine,Sabina A. Murphy,Benjamin M. Scirica,Mette Bjerre,Allan Flyvbjerg,Eugene Braunwald,David A. Morrow +9 more
TL;DR: OPG is independently associated with 30 day and 1 year risk of cardiovascular mortality and HF development after NSTE-ACS, and myocardial dysfunction may be a more important stimulus for OPG production than ischaemia in ACS.